Authors: Bhaavna Yalavarthi1 and Grace Collins2 In 2011, Friends published a study in Health Affairs that challenged the prevailing narrative of the time, which suggested that the U.S. Food and Drug Administration (FDA) was slower and less efficient than other regulatory authorities, such as the European Medicines Agency (EMA). This study provided evidence to the…
A novel drug regimen tested for the first time by researchers at Fred Hutch Cancer Center has shown great promise in preventing moderate to severe…
Here is a look back on all the FDA happenings from the month of January 2025.
9th Annual Blood Cover Art Contest is now open. In recognition of authors who published in Blood and images used in advancement of science, we…
Health Affairs’ Jeff Byers welcomes Kinika Young of The Leukemia & Lymphoma Society to the program to discuss a recent final rule/advisory issued by the…
This issue includes important information on the committee’s initiatives for the upcoming year, including recording podcasts, organizing informal meetups at different society meetings, collaborating with…
The experts in pediatric low-grade gliomas (pLGG) delineate the standard of care for frontline treatment of tumors not harboring the BRAF V600E mutation, outlining current…
Findings from RedirecTT-1 show responses across different dose levels of talquetamab/teclistamab among those with multiple myeloma.
Health Affairs’ Jeff Byers welcomes Kinika Young of The Leukemia & Lymphoma Society to the program to discuss a recent final rule/advisory issued by the…
